BCELライブシグナル | Getagraph.comで利益を最大化

買う 107970 min ago

@ $0.286

発行日: 15 2月 2024 @ 02:10

リターン: -70.94%

前回のシグナル: 2月 13 - 23:38

前回のシグナル: 売る

リターン: 16.83 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:48):

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types...

Stats
本日の出来高	35 390.00
平均出来高	714 654
時価総額	3.30M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.350 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.00400 (4.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Orwin John A	Buy	1	Series A Junior Preferred Stock
2024-04-01	Serafini Tito	Sell	20 788	Class A Common Stock
2023-09-01	Orwin John A	Sell	22 951	Class A Common Stock
2023-09-01	Serafini Tito	Sell	8 393	Class A Common Stock
2023-09-01	Courtney Phillips	Sell	7 061	Class A Common Stock

INSIDER POWER
26.33
Last 95 transactions
Buy: 4 455 146 \| Sell: 2 042 595

Atreca Inc 相関

10 最も正の相関
GETVV	0.975
ENG	0.934
KZR	0.92
DRCT	0.918
CTMX	0.917
PSTX	0.916
JAN	0.914
ALLK	0.911
DAWN	0.909
CKPT	0.908

10 最も負の相関
BNIXU	-0.916
STAY	-0.907
PT	-0.899
NVCN	-0.894
DSPG	-0.893
SGEN	-0.886
CCRC	-0.879
XLNX	-0.879
CHNGU	-0.878
PPYAU	-0.878

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Atreca Inc 財務諸表

Annual	2022
収益:	$770 000
総利益:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2022
収益:	$770 000
総利益:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.95

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.